BeOne Medicines Ltd. (ONC) stock
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/301935% above fair value
$416.54+0.58 (+0.14%)
Close on Nov 13, 2026Market cap $47.36BP/E 53.4Yield –
BeOne Medicines operating margin
Operating margin is operating income as a percentage of revenue.
BeOne Medicines's operating margin for the twelve months ending Sep 30, 2026 was 17.8%. For fiscal 2025 it was 8.4%, against -14.9% the year before. The highest annual figure on record is 8.4% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8.4% | +23.3 |
| FY2024 | Dec 31, 2024 | -14.9% | +34.2 |
| FY2023 | Dec 31, 2023 | -49.1% | +77.3 |
| FY2022 | Dec 31, 2022 | -126.4% | −4.1 |
| FY2021 | Dec 31, 2021 | -122.3% | +414.4 |
| FY2020 | Dec 31, 2020 | -536.7% | −312.5 |
| FY2019 | Dec 31, 2019 | -224.2% | +131.9 |
| FY2018 | Dec 31, 2018 | -356.1% | −314.8 |
| FY2017 | Dec 31, 2017 | -41.3% | +10898.9 |
| FY2016 | Dec 31, 2016 | -10940.2% | −10296.5 |
| FY2015 | Dec 31, 2015 | -643.7% | −522.8 |
| FY2014 | Dec 31, 2014 | -120.9% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 22.2% | +10.6 |
| Q2 FY2026 | Jun 30, 2026 | 19.1% | +12.4 |
| Q1 FY2026 | Mar 31, 2026 | 16.5% | +15.5 |
| Q4 FY2025 | Dec 31, 2025 | 12.4% | +19.4 |
| Q3 FY2025 | Sep 30, 2025 | 11.5% | +23.6 |
| Q2 FY2025 | Jun 30, 2025 | 6.7% | +18.2 |
| Q1 FY2025 | Mar 31, 2025 | 1.0% | +35.8 |
| Q4 FY2024 | Dec 31, 2024 | -7.0% | +53.5 |
| Q3 FY2024 | Sep 30, 2024 | -12.0% | +5.1 |
| Q2 FY2024 | Jun 30, 2024 | -11.5% | +42.0 |
| Q1 FY2024 | Mar 31, 2024 | -34.8% | +48.1 |
| Q4 FY2023 | Dec 31, 2023 | -60.5% | +62.8 |
| Q3 FY2023 | Sep 30, 2023 | -17.1% | +95.9 |
| Q2 FY2023 | Jun 30, 2023 | -53.5% | +75.1 |
| Q1 FY2023 | Mar 31, 2023 | -82.9% | +61.7 |
| Q4 FY2022 | Dec 31, 2022 | -123.3% | +143.9 |
| Q3 FY2022 | Sep 30, 2022 | -113.1% | +110.9 |
| Q2 FY2022 | Jun 30, 2022 | -128.6% | +187.9 |
| Q1 FY2022 | Mar 31, 2022 | -144.6% | −156.2 |
| Q4 FY2021 | Dec 31, 2021 | -267.2% | +217.2 |
| Q3 FY2021 | Sep 30, 2021 | -224.0% | +259.3 |
| Q2 FY2021 | Jun 30, 2021 | -316.6% | +230.2 |
| Q1 FY2021 | Mar 31, 2021 | 11.6% | +729.5 |
| Q4 FY2020 | Dec 31, 2020 | -484.4% | +197.6 |
| Q3 FY2020 | Sep 30, 2020 | -483.2% | +139.5 |
| Q2 FY2020 | Jun 30, 2020 | -546.8% | −511.5 |
| Q1 FY2020 | Mar 31, 2020 | -717.9% | −494.7 |
| Q4 FY2019 | Dec 31, 2019 | -682.1% | −203.4 |
| Q3 FY2019 | Sep 30, 2019 | -622.8% | −344.0 |
| Q2 FY2019 | Jun 30, 2019 | -35.3% | +273.5 |
| Q1 FY2019 | Mar 31, 2019 | -223.2% | +117.2 |
| Q4 FY2018 | Dec 31, 2018 | -478.6% | +92.5 |
| Q3 FY2018 | Sep 30, 2018 | -278.8% | −331.0 |
| Q2 FY2018 | Jun 30, 2018 | -308.8% | – |
| Q1 FY2018 | Mar 31, 2018 | -340.5% | – |
| Q4 FY2017 | Dec 31, 2017 | -571.1% | – |
| Q3 FY2017 | Sep 30, 2017 | 52.2% | – |
See a number that looks wrong?